Özlem Özdedeoğlu
Research Subjects
Research Interests
Özlem Özdedeoğlu has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Gözde Köycü Buhari
Department of Immunology and Allergy, University of Health Sciences, Ankara Ataturk Sanatoryum Training and Research Hospital
5 shared publications - Hale Ateş
Hlth Sci Univ, Ataturk Chest Dis & Thorac Surg Training & Res Ho, Clin Immunol & Allergy, Ankara, Turkiye
5 shared publications - Kurtuluş Aksu
Department of Allergy and Clinical Immunology, Ankara Atatürk Sanatorium Training and Research Hospital, University of Health Sciences, Ankara 06290, Türkiye
5 shared publications - Buket Başa Akdoğan
Immunology and Allergy, Istanbul Allergy Center, 34718 Istanbul, Türkiye
4 shared publications - Ferda Öner Erkekol
Clinic of Immunology and Allergic Diseases, Ankara Yildirim Beyazit University, Faculty of Medicine, Ankara City Hospital
4 shared publications - Ilkay Koca Kalkan
Department of Immunology and Allergy, University of Health Sciences, Ankara Ataturk Sanatoryum Training and Research Hospital
4 shared publications
Latest Publications
- Open Access
- 26 March 2024
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 72 (1) , 71-81
Results of omalizumab treatment in chronic eosinophilic pneumonia: Real-life data
Introduction: Recurrences occur when corticosteroid therapy is discontinued or reduced during the treatment of chronic eosinophilic pneumonia (CEP). The probability of recurrence is once in 50% of patients and twice or more in 25%. In such instances, new treatment options are deemed necessary. This study aims to assess the efficacy of omalizumab treatment as a steroid -sparing drug in patients with CEP. Materials and Methods: The clinical features of patients treated with omalizumab for recurrent CEP were evaluated retrospectively before and after treatment. All data from patients and diagnoses were reviewed. The effects of treatment on recurrence rate, oral corticosteroid (OCS) use and lung functions, peripheral eosinophil values, and symptom scores were evaluated. Radiological regression was also evaluated. Results: In the final analysis, we included ten patients with a median follow-up of 22 months after initiation of omalizumab. During this follow-up period, the results were associated with a significant reduction in the number of asthma attacks per year, the number of CEP relapses, the rate of hospitalization, the amount of corticosteroids consumed daily, and the total corticosteroid dose. In addition, improvement was observed in the symptom scores and lung functions of the patients. Systemic steroids were completely discontinued in two patients receiving omalizumab treatment. In other patients, the mean steroid dose was reduced by 77.2 percent in the first year of omalizumab treatment and 82 percent in the second year, respectively. Nevertheless, there was no elevation in peripheral eosinophil count, and radiological regression was observed. Conclusion: Omalizumab can be an effective treatment for CEP and can be used as a steroid -sparing agent.
- 26 March 2024
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 72 (1) , 71-81
Open AccessResults of omalizumab treatment in chronic eosinophilic pneumonia: Real-life data
Introduction: Recurrences occur when corticosteroid therapy is discontinued or reduced during the treatment of chronic eosinophilic pneumonia (CEP). The probability of recurrence is once in 50% of patients and twice or more in 25%. In such instances, new treatment options are deemed necessary. This study aims to assess the efficacy of omalizumab treatment as a steroid -sparing drug in patients with CEP. Materials and Methods: The clinical features of patients treated with omalizumab for recurrent CEP were evaluated retrospectively before and after treatment. All data from patients and diagnoses were reviewed. The effects of treatment on recurrence rate, oral corticosteroid (OCS) use and lung functions, peripheral eosinophil values, and symptom scores were evaluated. Radiological regression was also evaluated. Results: In the final analysis, we included ten patients with a median follow-up of 22 months after initiation of omalizumab. During this follow-up period, the results were associated with a significant reduction in the number of asthma attacks per year, the number of CEP relapses, the rate of hospitalization, the amount of corticosteroids consumed daily, and the total corticosteroid dose. In addition, improvement was observed in the symptom scores and lung functions of the patients. Systemic steroids were completely discontinued in two patients receiving omalizumab treatment. In other patients, the mean steroid dose was reduced by 77.2 percent in the first year of omalizumab treatment and 82 percent in the second year, respectively. Nevertheless, there was no elevation in peripheral eosinophil count, and radiological regression was observed. Conclusion: Omalizumab can be an effective treatment for CEP and can be used as a steroid -sparing agent.
- Open Access
- 29 February 2024
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 5 (1) , 9-15
Safety of partial selective COX-2 inhibitors in patients with cross-reactive NSAID hypersensitivity and factors affecting safety
Aims: Partial selective COX-2 inhibitors, such as nimesulide, or meloxicam are tolerated by the majority of the patients with cross-reactive NSAID hypersensitivity. This study aimed to obtain more information about the safety of partial selective COX-2 inhibitors; nimesulide and meloxicam in non-immunologic type, cross-reactive NSAID hypersensitivity and to detect risk factors for intolerance to these drugs. Methods: This is a retrospective study of patients with suggestive of cross-reactive NSAID hypersensitivity who admitted to our clinic over a period of 10 years. Patients who had a reliable history of immediate type NSAIDs hypersensitivity with at least 2 chemically unrelated class and/or positive ASA provocation test and who underwent alternative drug provocation test with partial selective COX-2 inhibitors (nimesulide and/or meloxicam) were included to study. Patients’ demographics, comorbidities, atopy status, duration of NSAID hypersensitivity, total number of reactions, reaction grades, clinical phenotypes, pulmonary function test parameters and results of alternative drug provocation test results are recorded. Patients with and without reactions during alternative provocation tests with nimesulide and/or meloxicam were compared in terms of these data. Results: A total of 560 patients were included in the study, 378 (67.5%) of them were female. Allergic comorbidities were detected in 394 (72.6%) patients. Asthma, other drug allergies and nasal polyp were the most common comorbidities. Alternative drug provocation test positivity with nimesulide and/or meloxicam was detected in 50 of 560 (8.9%) patients. Provocation test positivity was 33/541 (6.1%) with nimesulide, 30/517 (5.8%) with meloxicam and 13/498 (2.3%) with both nimesulide and meloxicam. Duration of NSAID hypersensitivity was shorter and allergic comorbidities, asthma, nasal polyp and the coexistence of asthma and nasal polyp were more common in patients with a positive provocation test. Conclusion: The partial selective COX-2 inhibitors nimesulide and meloxicam are well tolerated alternatives in patients with cross-reactive NSAID hypersensitivity. Hypersensitivity to these drugs is significantly higher in patients with asthma and/or nasal polyp than other group of cross-reactive NSAID hypersensitive patients and also in patients with a shorter duration of NSAID hypersensitivity.
- 29 February 2024
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 5 (1) , 9-15
Open AccessSafety of partial selective COX-2 inhibitors in patients with cross-reactive NSAID hypersensitivity and factors affecting safety
Aims: Partial selective COX-2 inhibitors, such as nimesulide, or meloxicam are tolerated by the majority of the patients with cross-reactive NSAID hypersensitivity. This study aimed to obtain more information about the safety of partial selective COX-2 inhibitors; nimesulide and meloxicam in non-immunologic type, cross-reactive NSAID hypersensitivity and to detect risk factors for intolerance to these drugs. Methods: This is a retrospective study of patients with suggestive of cross-reactive NSAID hypersensitivity who admitted to our clinic over a period of 10 years. Patients who had a reliable history of immediate type NSAIDs hypersensitivity with at least 2 chemically unrelated class and/or positive ASA provocation test and who underwent alternative drug provocation test with partial selective COX-2 inhibitors (nimesulide and/or meloxicam) were included to study. Patients’ demographics, comorbidities, atopy status, duration of NSAID hypersensitivity, total number of reactions, reaction grades, clinical phenotypes, pulmonary function test parameters and results of alternative drug provocation test results are recorded. Patients with and without reactions during alternative provocation tests with nimesulide and/or meloxicam were compared in terms of these data. Results: A total of 560 patients were included in the study, 378 (67.5%) of them were female. Allergic comorbidities were detected in 394 (72.6%) patients. Asthma, other drug allergies and nasal polyp were the most common comorbidities. Alternative drug provocation test positivity with nimesulide and/or meloxicam was detected in 50 of 560 (8.9%) patients. Provocation test positivity was 33/541 (6.1%) with nimesulide, 30/517 (5.8%) with meloxicam and 13/498 (2.3%) with both nimesulide and meloxicam. Duration of NSAID hypersensitivity was shorter and allergic comorbidities, asthma, nasal polyp and the coexistence of asthma and nasal polyp were more common in patients with a positive provocation test. Conclusion: The partial selective COX-2 inhibitors nimesulide and meloxicam are well tolerated alternatives in patients with cross-reactive NSAID hypersensitivity. Hypersensitivity to these drugs is significantly higher in patients with asthma and/or nasal polyp than other group of cross-reactive NSAID hypersensitive patients and also in patients with a shorter duration of NSAID hypersensitivity.
- 21 April 2023
- Published by Taylor & Francis in Journal of Asthma
- Vol. 60 (10) , 1862-1868
Evaluation of the clinical features and laboratory data of patients with severe asthma classified as super-responder or non super-responder to omalizumab treatment: a single-center real-life study
Introduction Omalizumab is used for the treatment of severe allergic asthma. Objective The aim of this study was to evaluate the clinical features and laboratory data of patients with severe allergic asthma classified as super-responder or non super-responder to omalizumab. Methods Comparisons were made of the laboratory data and clinical features of patients with severe allergic asthma. Patients who had no asthma exacerbation, no oral corticosteroid (OCS) use, asthma control test (ACT) score >20 and forced expiratory volume in 1 second (FEV1) >80% were considered super-responder after omalizumab. Results A total of 90 patients were included in the study, comprising 19 (21.1%) males. The age at onset of asthma, allergic rhinitis rate, number of endoscopic sinus surgeries (ESS), intranasal corticosteroid (INS) use, baseline FEV 1 (%) and ACT score were significantly higher in the omalizumab super-responder group (p = 0.013, p = 0.015, p = 0.002, p = 0.001, p = 0.001 and p < 0.001, respectively). The duration of asthma, rate of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), regular use of OCS, baseline eosinophil count and eosinophil/lymphocyte ratio were significantly higher in the omalizumab non super-responder group (p = 0.015, p < 0.001, p = 0.004, p < 0.001 and p < 0.001, respectively). Blood eosinophil count (AUC: 0.187, p < 0.001), Eosinophil/Lymphocyte ratio (AUC: 0.150, p < 0.001) and FEV1 (%) (AUC:0.779, p = 0.001) were determined to have diagnostic value in predicting the treatment response to omalizumab of patients with severe allergic asthma. Conclusion High blood eosinophil levels, CRSwNP, and low pre-treatment lung capacity may affect omalizumab treatment response in patients with severe allergic asthma. These results should be supported by further multicentre real-life studies.
- 21 April 2023
- Published by Taylor & Francis in Journal of Asthma
- Vol. 60 (10) , 1862-1868
Evaluation of the clinical features and laboratory data of patients with severe asthma classified as super-responder or non super-responder to omalizumab treatment: a single-center real-life study
Introduction Omalizumab is used for the treatment of severe allergic asthma. Objective The aim of this study was to evaluate the clinical features and laboratory data of patients with severe allergic asthma classified as super-responder or non super-responder to omalizumab. Methods Comparisons were made of the laboratory data and clinical features of patients with severe allergic asthma. Patients who had no asthma exacerbation, no oral corticosteroid (OCS) use, asthma control test (ACT) score >20 and forced expiratory volume in 1 second (FEV1) >80% were considered super-responder after omalizumab. Results A total of 90 patients were included in the study, comprising 19 (21.1%) males. The age at onset of asthma, allergic rhinitis rate, number of endoscopic sinus surgeries (ESS), intranasal corticosteroid (INS) use, baseline FEV 1 (%) and ACT score were significantly higher in the omalizumab super-responder group (p = 0.013, p = 0.015, p = 0.002, p = 0.001, p = 0.001 and p < 0.001, respectively). The duration of asthma, rate of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), regular use of OCS, baseline eosinophil count and eosinophil/lymphocyte ratio were significantly higher in the omalizumab non super-responder group (p = 0.015, p < 0.001, p = 0.004, p < 0.001 and p < 0.001, respectively). Blood eosinophil count (AUC: 0.187, p < 0.001), Eosinophil/Lymphocyte ratio (AUC: 0.150, p < 0.001) and FEV1 (%) (AUC:0.779, p = 0.001) were determined to have diagnostic value in predicting the treatment response to omalizumab of patients with severe allergic asthma. Conclusion High blood eosinophil levels, CRSwNP, and low pre-treatment lung capacity may affect omalizumab treatment response in patients with severe allergic asthma. These results should be supported by further multicentre real-life studies.
- Open Access
- 5 September 2021
- Published by Journal of Health Sciences and Medicine in Journal of Health Sciences and Medicine
- Vol. 4 (5) , 735-740
Direct cost analysis for patients with severe asthma receiving omalizumab treatment
Aim: The present study aims to reveal direct cost analysis of patients with severe allergic asthma receiving omalizumab treatment. Material and Methods: Twenty-two adults with severe allergic asthma who were treated with omalizumab and were routinely checked on the 16th week, 1st year, and 3rd year of treatment were included in the study. Clinical and demographic features of subjects were retrospectively documented before and after omalizumab treatment as well as pharmaceutical, emergency and hospital costs. Results: The monthly treatment cost per patient was higher during the 16th week, 1st year, and 3rd year (€411.80±190.84, €409.7±211.57, €404.2±157.30 respectively) when compared with the pre-treatment period (€107.91±48.62) (p
- 5 September 2021
- Published by Journal of Health Sciences and Medicine in Journal of Health Sciences and Medicine
- Vol. 4 (5) , 735-740
Open AccessDirect cost analysis for patients with severe asthma receiving omalizumab treatment
Aim: The present study aims to reveal direct cost analysis of patients with severe allergic asthma receiving omalizumab treatment. Material and Methods: Twenty-two adults with severe allergic asthma who were treated with omalizumab and were routinely checked on the 16th week, 1st year, and 3rd year of treatment were included in the study. Clinical and demographic features of subjects were retrospectively documented before and after omalizumab treatment as well as pharmaceutical, emergency and hospital costs. Results: The monthly treatment cost per patient was higher during the 16th week, 1st year, and 3rd year (€411.80±190.84, €409.7±211.57, €404.2±157.30 respectively) when compared with the pre-treatment period (€107.91±48.62) (p
- Open Access
- 23 August 2021
- Published by Turkish National Society of Allergy and Clinical Immunology in Asthma Allergy Immunology
- Vol. 19 (2) , 100-109
Can Fractional Exhaled Nitric Oxide with Blood Eosinophil Count Have a Place in the Diagnostic Algorithm for Asthma?
Can Fractional Exhaled Nitric Oxide with Blood Eosinophil Count Have a Place in the Diagnostic Algorithm for Asthma?
- 23 August 2021
- Published by Turkish National Society of Allergy and Clinical Immunology in Asthma Allergy Immunology
- Vol. 19 (2) , 100-109
Open AccessCan Fractional Exhaled Nitric Oxide with Blood Eosinophil Count Have a Place in the Diagnostic Algorithm for Asthma?
Can Fractional Exhaled Nitric Oxide with Blood Eosinophil Count Have a Place in the Diagnostic Algorithm for Asthma?
- Open Access
- 30 April 2020
- Published by Turkish National Society of Allergy and Clinical Immunology in Asthma Allergy Immunology
- Vol. 18 (1) , 51-53
Successful Desensitization with Ferric Carboxymaltose
Successful Desensitization with Ferric Carboxymaltose
- 30 April 2020
- Published by Turkish National Society of Allergy and Clinical Immunology in Asthma Allergy Immunology
- Vol. 18 (1) , 51-53
Open AccessSuccessful Desensitization with Ferric Carboxymaltose
Successful Desensitization with Ferric Carboxymaltose